Payment overview · 2025
General Payments
$1,114.11
65 reported records · 13 companies
Healthcare provider profile · identity verified
Ashley Burleson Pullen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MADISON, MS · NPI 1942400403
Verified facts
What the public records show
CMS Open Payments records show Ashley Burleson Pullen, M.D. received $1,114.11 in general payments during 2025 across 65 reported records.
ABBVIE INC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $368.79 | 33.1% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $250.85 | 22.5% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.09 | 8.3% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.21 | 7.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.86 | 7.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.00 | 5.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.81 | 3.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.71 | 3.6% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $32.42 | 2.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.00 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.16 | 1.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $13.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,114.11 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $250.85 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $164.06 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $148.78 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $146.90 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.79 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $84.21 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.09 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.09 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.45 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $58.00 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.81 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $39.71 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $13.37 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $4.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 736 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 405 | 118 |
| Omeprazole | Omeprazole | 326 | 91 |
| Lisinopril | Lisinopril | 312 | 94 |
| Losartan Potassium | Losartan Potassium | 301 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 74 |
| Gabapentin | Gabapentin | 246 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 68 |
| Metformin Hcl | Metformin Hcl | 237 | 66 |
| Simvastatin | Simvastatin | 211 | 51 |
| Montelukast Sodium | Montelukast Sodium | 203 | 59 |
| Glimepiride | Glimepiride | 184 | 45 |
| Trazodone Hcl | Trazodone Hcl | 174 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 42 |
| Furosemide | Furosemide | 162 | 49 |
| Metformin Hcl Er | Metformin Hcl | 153 | 36 |
| Meloxicam | Meloxicam | 151 | 56 |
| Sertraline Hcl | Sertraline Hcl | 144 | 40 |
| Alprazolam | Alprazolam | 135 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 36 |
| Spironolactone | Spironolactone | 120 | 30 |
| Potassium Chloride | Potassium Chloride | 116 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 32 |
| Ozempic | Semaglutide | 102 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 39 |
| Synthroid | Levothyroxine Sodium | 98 | 22 |
| Bupropion Xl | Bupropion Hcl | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 22 |
| Pregabalin | Pregabalin | 82 | 19 |
| Jardiance | Empagliflozin | 81 | 22 |
| Celecoxib | Celecoxib | 76 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 22 |
| Carvedilol | Carvedilol | 74 | 21 |
| Famotidine | Famotidine | 74 | 32 |
| Januvia | Sitagliptin Phosphate | 73 | 14 |
| Glipizide | Glipizide | 72 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 20 |
| Allopurinol | Allopurinol | 71 | 21 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Eliquis | Apixaban | 69 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 14 |
| Atenolol | Atenolol | 66 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 19 |
| Nifedipine Er | Nifedipine | 65 | 17 |
| Methylprednisolone | Methylprednisolone | 64 | 57 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 43 |
| Azithromycin | Azithromycin | 60 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 17 |
| Estradiol | Estradiol | 55 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Ezetimibe | Ezetimibe | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Fluconazole | Fluconazole | 41 | 27 |
| Buspirone Hcl | Buspirone Hcl | 40 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 14 |
| Tramadol Hcl | Tramadol Hcl | 38 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | 19 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Prednisone | Prednisone | 22 | 17 |
| Azelastine Hcl | Azelastine Hcl | 21 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Cephalexin | Cephalexin | 20 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Valsartan | Valsartan | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,114.11 · 65 records | ABBVIE INC. | AIRSUPRA, AREXVY, Azstarys, BREZTRI, CREON, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, JATENZO, KISUNLA, LINZESS, NURTEC ODT, Ozempic, PROCLAIM, QULIPTA, REXULTI, Rybelsus, SHINGRIX, Saxenda, TRELEGY ELLIPTA, Tresiba, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error